Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee

These results agree with the available literature, showing that an acute course of IN esketamine treatment was not associated with high levels of drug liking or cravings, and this did not increase through the course of eight treatments. Though larger studies are needed, esketamine does not appear to be associated with significant abuse liability when used in an acute course of treatment for patients with MDD-TRD. These are important results for this patient population and for clinical practice.

Authors

Institutions

Publication Details

Journal
Therapeutic Advances in Drug Safety
Published
2025-06-19
DOI
https://doi.org/10.1177/20420986251347360
Citations
2
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
2.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee

Nisha Ravindran, Sean M. Nestor, André Do, Karthikeyan Ganapathy et al.
2 citations
Therapeutic Advances in Drug Safety
Treatment of Major Depression
2.79
article

Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee

Nisha Ravindran, Sean M. Nestor, André Do, Karthikeyan Ganapathy, Jennifer Swainson, Gustavo Vázquez, Gilmar Gutiérrez, Anusha Baskaran, Raymond W. Lam, Peter Giacobbe, Annette Kowara
article en
2 citations

Abstract

These results agree with the available literature, showing that an acute course of IN esketamine treatment was not associated with high levels of drug liking or cravings, and this did not increase through the course of eight treatments. Though larger studies are needed, esketamine does not appear to be associated with significant abuse liability when used in an acute course of treatment for patients with MDD-TRD. These are important results for this patient population and for clinical practice.

Therapeutic Advances in Drug SafetyVol. 16
Providence Health Care (CA), Sunnybrook Health Science Centre (CA), Centre for Addiction and Mental Health (CA), University of British Columbia (CA), University of Alberta (CA), University of Toronto (CA), Queen's University (CA), Alberta Hospital Edmonton (CA), Misericordia Community Hospital (CA), Health Sciences Centre (CA), Université de Montréal (CA)
Good health and well-being
Openalex Percentile: Top 10%
Treatment of Major Depression
2.79
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee — Nisha Ravindran, Sean M. Nestor, et al. · Therapeutic Advances in Drug Safety (2025) | TGRS Research Map | TGRS